Zentalis

Zentalis : Discovering and developing a broad pipeline of potentially best-in-class oncology candidates, which include lead candidate ZN-c3, a Wee1 inhibitor targeting advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC) and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Multiple mono and combo trials are ongoing/planned across the pipeline.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States

Company Participants at Zentalis R&D Day

  • Anthony Sun, CEO

Lead Programs

ZN-c5: Oral SERD

oral selective estrogen receptor degrader (SERD)

Indication Phase
Breast Cancer 1/2

ZN-c3: WEE1

oral inhibitor of WEE1

Indication Phase
Solid Tumors 1/2

ZN-d5: BCL-2

oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies IND

ZN-e4: EGFR

oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)

Indication Phase
NSCLC 1/2

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Matrix Capital Management Co. LP 16.45 9,199,973 199.27 13F 6/30/22
Fidelity Management & Research Co. LLC 11.88 6,645,117 143.93 13F 6/30/22
Vanguard Group, Inc. (Subfiler) 7.84 4,383,727 94.95 13F 6/30/22
T. Rowe Price Associates, Inc. (Investment Management) 7.69 4,298,551 93.11 13F 6/30/22
Avidity Partners Management LP 6.41 3,585,881 77.67 13F 6/30/22
The Vanguard Group, Inc. 7.03 3,186,986 69.03 Stakes 12/31/21
State Street Corp. 5.58 3,119,734 67.57 13F 6/30/22
Tybourne Capital Management (HK) Ltd. 4.34 2,426,095 52.55 13F 6/30/22
Viking Global Investors LP 3.62 2,026,656 43.90 13F 6/30/22
Decheng Capital Management Iii Cayman LLC 3.26 1,824,583 39.52 13F 6/30/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.